T0	Participants 36 64	chronic hepatitis B patients
T1	Participants 227 320	chronic hepatitis B patients treated with different doses of recombinant hepatitis B vaccine.
T2	Participants 329 420	Seventy-two chronic hepatitis B patients who did not use any anti-HBV drugs within 6 months
T3	Participants 516 617	The patients in different groups were treated with different doses of recombinant hepatitis B vaccine
T4	Participants 1151 1185	patients who were ELISPOT positive
T5	Participants 2224 2258	patients with chronic hepatitis B.